Latest Health News

EVZ Limited has issued earnings guidance for FY2025, forecasting revenue between $108 million and $110 million with EBITDA expected around $5.2 million to $5.4 million. The final audited results will be released in late August.

Adherium Limited has successfully completed a $4.49 million entitlement offer, combining institutional and retail components, to fund expansion of its Hailie® digital respiratory monitoring platform.

Bowen Coking Coal Ltd has been hit with a $6.8 million statutory demand from contractor BUMA Australia, raising the spectre of insolvency if unresolved within 21 days. The dispute centers on claims and counterclaims involving liquidated damages.

Metallium Ltd has completed a A$50 million institutional raise, secured a Texas site, and validated its commercial Flash Joule Heating reactor, setting the stage for its first U.S. metals recovery plant commissioning by year-end 2025.

Mirrabooka Investments reports a 26% drop in net profit for FY25 but maintains its fully franked dividend, supported by a significant $85 million capital raise. The fund’s portfolio return lags the benchmark amid sector headwinds, yet long-term performance remains robust.

RLF AgTech reports a robust 74% increase in customer cash receipts for FY2025, alongside a significant expansion of its Australian distribution network and strong pre-orders from China, signaling a promising start to FY2026.

IDT Australia has signed a memorandum with NASDAQ-listed Gelteq to establish a dedicated gel-based product manufacturing facility, marking a strategic expansion in pharmaceutical delivery technologies.

Visionflex Group delivered a standout Q4 FY25, posting $2.1 million in cash receipts and securing transformative contracts that underpin its expanding virtual healthcare footprint.

Triton Minerals updates investors on ongoing legal disputes over its Mozambique graphite project SSAP, rejecting a recent counterproposal and enacting strict cost-cutting measures to preserve cash.

Future Generation Global has reported a strong 20.8% investment portfolio return for the year ending June 2025, prompting an increase in its fully franked interim dividend to 4.0 cents per share. This marks the sixth consecutive year of dividend growth for the ASX-listed investment company.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

Alliance Nickel has strengthened its financial position with an additional A$1.2 million unsecured loan and extended existing facilities, while reaffirming the commercial viability of its NiWest Nickel-Cobalt Project through a comprehensive Definitive Feasibility Study.